Corbus Pharmaceuticals Target of Unusually Large Options Trading (NASDAQ:CRBP)

Key Points

• Unusually heavy options activity: Traders bought 10,124 put options on CRBP, about 690% above average daily volume, signaling elevated bearish hedging or speculation. The stock fell to $6.68, near its 12-month low.
• Analyst sentiment remains mixed but broadly positive: Eight analysts rate Corbus a Buy versus two Sells, producing a “Moderate Buy” consensus and an average $41 price target, although several firms recently lowered their targets.
• Clinical progress contrasts with financial pressure: Corbus reported promising early weight-loss results for oral drug candidate CRB-913, while its latest quarterly loss of $1.81 per share missed expectations and analysts project a full-year loss of $5.62 per share.

Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP - Get Free Report) was the recipient of unusually large options trading on Tuesday. Traders purchased 10,124 put options on the stock. This is an increase of approximately 690% compared to the average daily volume of 1,282 put options.

Wall Street Analysts Forecast Growth

CRBP has been the topic of several analyst reports. Wall Street Zen cut Corbus Pharmaceuticals from a "sell" rating to a "strong sell" rating in a research report on Saturday, August 8th. Oppenheimer reduced their target price on Corbus Pharmaceuticals from $52.00 to $48.00 and set an "outperform" rating for the company in a report on Friday, August 7th. HC Wainwright reaffirmed a "buy" rating and set a $35.00 price target on shares of Corbus Pharmaceuticals in a report on Monday. Wedbush dropped their price objective on Corbus Pharmaceuticals from $38.00 to $30.00 and set an "outperform" rating on the stock in a research report on Wednesday, May 27th. Finally, Guggenheim reissued a "buy" rating on shares of Corbus Pharmaceuticals in a research report on Tuesday, May 26th. Eight research analysts have rated the stock with a Buy rating and two have issued a Sell rating to the stock. According to MarketBeat, the company presently has a consensus rating of "Moderate Buy" and an average target price of $41.00.

Corbus Pharmaceuticals Price Performance

• Corbus Pharmaceuticals NASDAQ: CRBP Gives a Bold Buy Signal

Shares of CRBP traded down $1.40 on Tuesday, reaching $6.68. The company's stock had a trading volume of 2,830,192 shares, compared to its average volume of 435,593. The stock's 50 day simple moving average is $9.75 and its two-hundred day simple moving average is $9.45. The stock has a market capitalization of $124.73 million, a P/E ratio of -1.08 and a beta of 2.63. Corbus Pharmaceuticals has a 12-month low of $6.32 and a 12-month high of $20.56.

Corbus Pharmaceuticals (NASDAQ:CRBP - Get Free Report) last issued its quarterly earnings results on Thursday, August 6th. The biopharmaceutical company reported ($1.81) earnings per share for the quarter, missing the consensus estimate of ($1.26) by ($0.55). Analysts expect that Corbus Pharmaceuticals will post -5.62 earnings per share for the current year.

Insider Buying and Selling

In other news, insider Nishant Saxena acquired 2,600 shares of Corbus Pharmaceuticals stock in a transaction on Tuesday, August 11th. The stock was acquired at an average cost of $9.63 per share, for a total transaction of $25,038.00. Following the purchase, the insider owned 77,900 shares in the company, valued at $750,177. This trade represents a 3.45% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO Yuval Cohen sold 17,000 shares of Corbus Pharmaceuticals stock in a transaction dated Friday, August 7th. The stock was sold at an average price of $10.08, for a total transaction of $171,360.00. Following the completion of the transaction, the chief executive officer directly owned 157,316 shares of the company's stock, valued at $1,585,745.28. This trade represents a 9.75% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. 3.50% of the stock is currently owned by company insiders.

Institutional Trading of Corbus Pharmaceuticals

Several institutional investors and hedge funds have recently modified their holdings of CRBP. Engineers Gate Manager LP boosted its stake in shares of Corbus Pharmaceuticals by 109.9% in the second quarter. Engineers Gate Manager LP now owns 29,800 shares of the biopharmaceutical company's stock worth $280,000 after acquiring an additional 15,600 shares during the period. Pale Fire Capital SE raised its stake in Corbus Pharmaceuticals by 13.8% during the 2nd quarter. Pale Fire Capital SE now owns 24,301 shares of the biopharmaceutical company's stock valued at $228,000 after purchasing an additional 2,951 shares during the period. Bank of New York Mellon Corp purchased a new position in Corbus Pharmaceuticals in the 2nd quarter worth approximately $425,000. Seven Fleet Capital Management LP lifted its holdings in Corbus Pharmaceuticals by 51.0% in the 1st quarter. Seven Fleet Capital Management LP now owns 85,687 shares of the biopharmaceutical company's stock worth $805,000 after purchasing an additional 28,937 shares in the last quarter. Finally, Bank of America Corp DE boosted its stake in Corbus Pharmaceuticals by 53,592.3% in the 1st quarter. Bank of America Corp DE now owns 13,960 shares of the biopharmaceutical company's stock worth $131,000 after purchasing an additional 13,934 shares during the period. 64.64% of the stock is currently owned by institutional investors.

More Corbus Pharmaceuticals News

Here are the key news stories impacting Corbus Pharmaceuticals this week:

• Positive Sentiment: Promising CRB-913 obesity data: Corbus reported statistically significant and clinically meaningful average weight loss of 5% after 12 weeks at the 60-mg dose in the Phase 1b CANYON-1 trial. No weight-loss plateau was observed, and the oral, non-incretin treatment showed generally favorable gastrointestinal tolerability. Corbus Pharmaceuticals Announces Positive Topline Data from CANYON-1 Study
• Positive Sentiment: Potential differentiation from GLP-1 drugs: Psychiatric adverse events were broadly in line with GLP-1 medicines, while the emerging gastrointestinal safety profile could support CRB-913’s positioning as an oral alternative in the obesity market. The data will be presented as a late-breaking disclosure at ObesityWeek 2026. Corbus Pharmaceuticals Obesity Drug Avoids Depressive Effects
• Positive Sentiment: Analyst support: HC Wainwright reaffirmed its Buy rating and maintained a $35 price target, implying substantial upside if CRB-913 continues to deliver positive clinical results.
• Positive Sentiment: Heavy call buying: Investors purchased 7,228 call options on Monday, roughly 523% above typical daily volume, indicating elevated speculative interest in a potential rebound or additional favorable news.
• Neutral Sentiment: Further investor interpretation: A transcript discussing the Phase 1b results and CRB-913’s potential as a weight-loss therapy may provide additional details, but the study remains early-stage and requires further clinical validation. CRB-913 Phase 1b Topline Results Transcript
• Negative Sentiment: Unusually high put activity: Investors purchased 10,124 put options Tuesday, approximately 690% above normal volume. This bearish hedging or speculative activity may be contributing to pressure on CRBP despite the positive trial announcement.

About Corbus Pharmaceuticals

Corbus Pharmaceuticals Holdings, Inc is a clinical-stage biopharmaceutical company dedicated to the development and commercialization of therapeutic candidates for rare, life-threatening inflammatory and fibrotic diseases. The company's lead investigational therapy, lenabasum, is a synthetic, oral cannabinoid receptor type 2 (CB2) agonist designed to resolve chronic inflammation by harnessing the body's innate resolution pathways. Corbus operates by advancing small-molecule compounds through preclinical and clinical studies to address unmet medical needs in autoimmune and inflammatory disorders.

Lenabasum is currently under evaluation in a Phase 3 clinical trial for diffuse cutaneous systemic sclerosis (dcSSc) and in a Phase 2 study for cystic fibrosis–related inflammation.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.